Cargando…

Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer

Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiographic syndrome with seizures, headache, altered mental status and visual disturbances. It is typically associated with posterior cerebral white matter oedema on neuroimaging. There is an increasing number of cases of PRES repor...

Descripción completa

Detalles Bibliográficos
Autores principales: Abughanimeh, Omar K, Qasrawi, Ayman H, Tahboub, Mohammad Y, Abu Ghanimeh, Mouhanna K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The British Institute of Radiology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159153/
https://www.ncbi.nlm.nih.gov/pubmed/30363210
http://dx.doi.org/10.1259/bjrcr.20170033
_version_ 1783358571771068416
author Abughanimeh, Omar K
Qasrawi, Ayman H
Tahboub, Mohammad Y
Abu Ghanimeh, Mouhanna K
author_facet Abughanimeh, Omar K
Qasrawi, Ayman H
Tahboub, Mohammad Y
Abu Ghanimeh, Mouhanna K
author_sort Abughanimeh, Omar K
collection PubMed
description Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiographic syndrome with seizures, headache, altered mental status and visual disturbances. It is typically associated with posterior cerebral white matter oedema on neuroimaging. There is an increasing number of cases of PRES reported with different chemotherapeutic protocols. However, PRES is rarely reported in association with irinotecan, fluorouracil and folinic acid (FOLFIRI). We report a 28-year-old female patient with a history of Stage IV gastric cancer who presented with abdominal pain and recurrent vomiting that was thought to be related to a partial intestinal obstruction secondary to peritoneal metastasis. Eventually, she was treated with FOLFIRI. A few hours after initiation of the fluorouracil infusion in the second cycle, she developed a tonic-clonic seizure. MRI of the brain showed multiple bilateral T(2) and flair hyperintense cortical and subcortical lesions suggestive of PRES. Other causes of PRES were excluded, as well as brain metastasis. Unfortunately, the patient developed septic shock and died a few days after her presentation.
format Online
Article
Text
id pubmed-6159153
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher The British Institute of Radiology
record_format MEDLINE/PubMed
spelling pubmed-61591532018-10-25 Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer Abughanimeh, Omar K Qasrawi, Ayman H Tahboub, Mohammad Y Abu Ghanimeh, Mouhanna K BJR Case Rep Case Report Posterior reversible encephalopathy syndrome (PRES) is a clinical-radiographic syndrome with seizures, headache, altered mental status and visual disturbances. It is typically associated with posterior cerebral white matter oedema on neuroimaging. There is an increasing number of cases of PRES reported with different chemotherapeutic protocols. However, PRES is rarely reported in association with irinotecan, fluorouracil and folinic acid (FOLFIRI). We report a 28-year-old female patient with a history of Stage IV gastric cancer who presented with abdominal pain and recurrent vomiting that was thought to be related to a partial intestinal obstruction secondary to peritoneal metastasis. Eventually, she was treated with FOLFIRI. A few hours after initiation of the fluorouracil infusion in the second cycle, she developed a tonic-clonic seizure. MRI of the brain showed multiple bilateral T(2) and flair hyperintense cortical and subcortical lesions suggestive of PRES. Other causes of PRES were excluded, as well as brain metastasis. Unfortunately, the patient developed septic shock and died a few days after her presentation. The British Institute of Radiology 2017-11-17 /pmc/articles/PMC6159153/ /pubmed/30363210 http://dx.doi.org/10.1259/bjrcr.20170033 Text en © 2017 The Authors. Published by the British Institute of Radiology http://creativecommons.org/licenses/by/4.0/ This is an open access article under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
spellingShingle Case Report
Abughanimeh, Omar K
Qasrawi, Ayman H
Tahboub, Mohammad Y
Abu Ghanimeh, Mouhanna K
Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer
title Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer
title_full Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer
title_fullStr Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer
title_full_unstemmed Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer
title_short Posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer
title_sort posterior reversible encephalopathy syndrome while receiving irinotecan with fluorouracil and folinic acid for metastatic gastric cancer
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6159153/
https://www.ncbi.nlm.nih.gov/pubmed/30363210
http://dx.doi.org/10.1259/bjrcr.20170033
work_keys_str_mv AT abughanimehomark posteriorreversibleencephalopathysyndromewhilereceivingirinotecanwithfluorouracilandfolinicacidformetastaticgastriccancer
AT qasrawiaymanh posteriorreversibleencephalopathysyndromewhilereceivingirinotecanwithfluorouracilandfolinicacidformetastaticgastriccancer
AT tahboubmohammady posteriorreversibleencephalopathysyndromewhilereceivingirinotecanwithfluorouracilandfolinicacidformetastaticgastriccancer
AT abughanimehmouhannak posteriorreversibleencephalopathysyndromewhilereceivingirinotecanwithfluorouracilandfolinicacidformetastaticgastriccancer